Evidence map›Paper›PMID 39722013›Full record

ArticleBMC neurology2024

lncRNA six3os1 diagnoses acute stroke, predicts disease severity, and predicts post-stroke cognitive impairment.

Yan Liu, Rui Wang, Junsheng Zeng, Wei Zhao, Yanqiao Xiao, Heng Jiang, Te Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Blood-Based Biomarkers for Post-Stroke Cognitive Impairment.Current issues in molecular biology · 2026
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan Liu *Department of Neurology, The Affiliated Changsha Central Hospital, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China.
Rui Wang *Department of Neurology, Liaocheng People's Hospital, Liaocheng, 252000, Shandong, China.
Junsheng ZengDepartment of Neurology, The Affiliated Changsha Central Hospital, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China.
Wei ZhaoDepartment of Neurology, The Affiliated Changsha Central Hospital, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China.
Yanqiao XiaoDepartment of Neurology, The Affiliated Changsha Central Hospital, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China.
Heng JiangDepartment of Neurology, The Affiliated Changsha Central Hospital, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China.
Te WangDepartment of Neurology, The Affiliated Changsha Central Hospital, University of South China, No. 161 Shaoshan South Road, Changsha, 410004, Hunan, China. 2018050821@usc.edu.cn.

Funding

Scientific Research Project of Hunan Provincial Health Commission B202303076877
6 · The paper itself

Abstract

backgroundStroke is the main cause of death and disability. Post-stroke cognitive impairment (PSCI) is one of the most severe complications of stroke, which lacks effective biomarkers for its early detection.

objectiveThis study evaluated the significance of lncRNA SIX3OS1 in acute stroke and PSCI aiming to identify a novel biomarker. PATIENTS AND

methodsThe study enrolled 138 patients with acute stroke and 80 healthy individuals. By comparing the serum SIX3OS1 in acute stroke and healthy individuals, the significance of SIX3OS1 in diagnosing acute stroke, assessing disease severity, and predicting the risk of PSCI was revealed.

resultsSignificant upregulation of SIX3OS1 in acute stroke was observed, which discriminated patients with acute stroke from healthy individuals and indicated severe disease conditions of patients. There were 72 acute stroke patients who had PSCI accounting for 52.17% that showed a higher serum SIX3OS1 level than post-stroke cognitive normal patients. The increasing serum SIX3OS1 level was also identified as a risk factor for PSCI and could distinguish PSCI patients. Additionally, SIX3OS1 showed a negative correlation with the MoCA score of PSCI patients.

conclusionSerum SIX3OS1 level can be considered a biomarker for screening acute stroke and a predictor for PSCI.

Indexed as

BiomarkersCognitive DysfunctionRNA, Long NoncodingStrokeAgedFemaleHumansMaleMiddle AgedSeverity of Illness IndexBiomarkersRNA, Long NoncodingBiomarkerCognitive functionlncRNAStroke severity

Identifiers

PMID39722013
PMCPMC11670514

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.